

# AMYPAD-DPMS preliminary results: participants' baseline features

Daniele Altomare<sup>1,2</sup>, Lyduine Collij<sup>3</sup>, Valentina Garibotto<sup>4</sup>, Léa Poitrine<sup>1,2</sup>, Christian Moro<sup>1,2</sup>, Isadora Lopes Alves<sup>3</sup>, Ingrid van Maurik<sup>3</sup>, Johannes Berkhof<sup>3</sup>, Philip Scheltens<sup>3</sup>, Julien Delrieu<sup>5</sup>, José Luis Molinuevo<sup>6</sup>, Agneta Nordberg<sup>7</sup>, Frank Jessen<sup>8</sup>, Zuzana Walker<sup>9</sup>, Jean-François Demonet<sup>10</sup>, Rossella Gismondi<sup>11</sup>, Gill Farrar<sup>12</sup>, Frederik Barkhof<sup>3,9</sup>, Andrew Stephens<sup>11</sup>, Giovanni B Frisoni<sup>1,2</sup>, on behalf of the AMYPAD Consortium

<sup>1</sup>Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Switzerland. <sup>2</sup>Memory Clinic, Geneva University Hospitals, Switzerland. <sup>3</sup>Amsterdam UMC (VUmc), The Netherlands. <sup>4</sup>Department of Radiology and Medical Informatics, Geneva University Hospitals, Switzerland. <sup>5</sup>University Hospital of Toulouse and University of Toulouse, Toulouse, France. <sup>6</sup>BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. <sup>7</sup>Karolinska Institutet and University Hospital, Stockholm, Sweden. <sup>8</sup>University of Cologne and DZNE, Germany. <sup>9</sup>UCL, London, UK. <sup>10</sup>Lausanne University Hospital, Switzerland. <sup>11</sup>Life Molecular Imaging, Berlin, Germany. <sup>12</sup>GE Healthcare, Amersham, UK.

## Background

No definitive evidence on clinical utility and cost-effectiveness of amyloid-PET → No reimbursement


The AMYPAD Diagnostic and Patient Management Study (DPMS) aims to fill this evidence gap.

## Methods

AMYPAD-DPMS plans to enroll a total of 900 patients from 8 memory clinics

- 300 subjective cognitive decline plus (SCD+)
- 300 mild cognitive impairment (MCI)
- 300 dementia

Patients will be randomized into the 3 study arms (Figure).



## Results

So far, 732 patients (Table) enrolled from 8 European memory clinics (Geneva 193, Toulouse 129, Amsterdam 114, Barcelona 79, Cologne 71, London 64, Stockholm 45, Lausanne 37).

**Table**

Baseline features	SCD+ n=196	MCI n=330	Dementia n=206	p-value
Age	69 (10) <sup>b</sup>	72 (10) <sup>a</sup>	74 (10) <sup>a</sup>	<0.001
Gender, males	56% (109)	55% (183)	53% (109)	0.816
Education, years	14 (6) <sup>a</sup>	12 (5) <sup>b</sup>	12 (5) <sup>c</sup>	<0.001
MMSE	29 (2) <sup>a</sup> [1]	26 (4) <sup>b</sup> [4]	22 <sup>c</sup> (6)	<0.001
Amyloid-PET positivity	32% (40) <sup>c</sup> [70]	54% (103) <sup>b</sup> [139]	70% (74) <sup>a</sup> [100]	<0.001
HAD Anxiety	6 (5) [2]	6 (6) [5]	5 (5) [9]	0.330
HAD Depression	4 (4) [2]	4 (5) [5]	5 (5) [9]	0.121
BMI	26 (5) [5]	26 (4) [3]	25 (6) [11]	0.271
Reported cardiovascular events	35% (68)	33% (110)	36% (75)	0.766
Living in long-term care home	0% (0)	0% (1)	1% (3)	0.101

## Conclusion

Participants' features are as expected for a memory clinic population.

→ The inclusion criteria are selecting a sample representative of the larger memory clinic population  
 → This observation reassures on the generalizability of the final study results



**Table**

MMSE: Mini-Mental State Examination; BMI: body mass index; HAD: Hospital Anxiety and Depression score. Values are median (interquartile range) for continuous variables, or percentage (raw number) for categorical variables. Statistical analyses: Kruskal-Wallis rank sum test for continuous variables, test for equality of proportions for categorical variables. Post-hoc: <sup>a</sup> > <sup>b</sup> > <sup>c</sup>. [ ]: number of missing values.